Strategic Health Innovation Partnerships (SHIP): Tuberculosis Vaccine Development, HIV Vaccines and Prevention

Foreign collaborators (Israeli) may not apply for funding directly as PIs, but may be included as sub-contractors if they provide a service or capability that is not available among the project partners and/or not available locally.
Tuberculosis Vaccine Development: (1) To develop and investigate novel approaches to identify potential biomarkers or risk of infection or disease and, in the context of vaccine efficacy studies, correlates of vaccine-induced protection from infection or disease.
(2) To develop improved models for vaccination and challenge studies in animals and humans to understand protective immunity and evaluate pre-exposure; post-exposure anti-latency and therapeutic vaccines.
(3) To develop novel vaccine technologies across formulation, design and delivery. HIV Vaccines: (1) Vaccine platform development.
(2) Mucosal Immunity
(3) Hypothesis-driven, lab-intensive studies leveraging clinical samples.
HIV Prevention: New or improved HIV prevention methods, devices, drugs/biologicals, and combinations.
http://ship.mrc.ac.za/rfaTBHIV.htm